Organon announced on October 28, 2024, the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant. This acquisition expands Organon’s dermatology capabilities with VTAMA (tapinarof) cream, 1%, a novel nonbiologic, non-steroidal topical therapy.
VTAMA cream is approved by the U.S. Food and Drug Administration (FDA) for the treatment of mild, moderate, and severe plaque psoriasis in adults. The FDA is also reviewing a supplemental New Drug Application (sNDA) for VTAMA cream as a potential treatment for atopic dermatitis (AD) in adults and children two years of age and older, with a PDUFA action expected in the fourth quarter of 2024.
The integration of Dermavant's expertise into Organon's U.S. organization marks a new chapter in dermatology for the company. This strategic move aims to bring a patient-focused innovation to millions living with plaque psoriasis and potentially atopic dermatitis.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.